Beyond COVID-19: Ousted BARDA Chief’s Whistleblower Complaint Suggests Widespread Politicization of HHS Funding Decisions
Ousted BARDA Director Rick Bright's whistleblower complaint cites a long-pattern of political interference in scientific decisions making and could lead to overhauls in how BARDA and other HHS contracts are awarded to the drug industry. It could also impact how Congress funds BARDA, following a recent move by lawmakers to give the division more direct control of its funding.
You may also be interested in...
Congress wants HHS to explain why BARDA scientists were removed from leadership positions on COVID-19 vaccine contracts. It is just one of multiple examples of Democrats raising concerns that Operation Warp Speed could be hurting, not helping the COVID-19 response effort.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.